Comment: Humoral and T-cell Immunities to SARS-CoV-2 Vaccines: Safety, Efficacy, and Challenges in Autoimmune Neurology

Abstract

With the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA)vaccinations, we have been witnessing a new era in vaccinology because these vaccines do not contain viral proteins but mRNA or viral vectors that instruct the cells to make viralspecific protective antibodies. To effectively fight SARS-CoV-2 infection, however, these vaccines need to induce both humoral and cell-mediated immune responses, with antibodies that block viral replication and viral-specific T cells that kill viral-infected cells and generate antibodyproducing plasma cells and long-lived memory cells.